Apogee Therapeutics, Inc.
APGE
$82.93
-$1.67-1.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 76.13M | 70.88M | 66.92M | 62.80M | 56.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 305.27M | 285.60M | 283.42M | 270.83M | 241.79M |
| Operating Income | -305.27M | -285.60M | -283.42M | -270.83M | -241.79M |
| Income Before Tax | -274.34M | -255.57M | -253.44M | -237.50M | -205.29M |
| Income Tax Expenses | 274.00K | 278.00K | 234.00K | 173.00K | 101.00K |
| Earnings from Continuing Operations | -274.62 | -255.84 | -253.67 | -237.67 | -205.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -274.62M | -255.84M | -253.67M | -237.67M | -205.39M |
| EBIT | -305.27M | -285.60M | -283.42M | -270.83M | -241.79M |
| EBITDA | -303.65M | -284.18M | -282.33M | -270.10M | -241.42M |
| EPS Basic | -4.33 | -4.22 | -4.36 | -4.12 | -3.59 |
| Normalized Basic EPS | -2.70 | -2.63 | -2.72 | -2.57 | -2.24 |
| EPS Diluted | -4.33 | -4.22 | -4.36 | -4.12 | -3.59 |
| Normalized Diluted EPS | -2.70 | -2.63 | -2.72 | -2.57 | -2.24 |
| Average Basic Shares Outstanding | 254.23M | 242.76M | 232.65M | 230.67M | 228.76M |
| Average Diluted Shares Outstanding | 254.23M | 242.76M | 232.65M | 230.67M | 228.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |